© Copyright 2023, All Rights Reserved by Banty (our partner in clinical trial recruitment)
If you are taking PAXLOVID and are interested in seeing if you qualify for a clinical trial, it is important that you monitor your COVID-19 symptoms for 14 days following your last dose to help determine whether you experience COVID-19 symptom rebound.
The Pfizer C4671042 clinical trial is evaluating if an additional 5-day course of PAXLOVID may provide benefit for adults with rebound of COVID-19 symptoms and a SARS-CoV-2 infection within 14 days after completing an initial 5-day course of PAXLOVID.
Being in the study is voluntary. Even if you decide to join and then change your mind, you can stop participating at any time.
People who are eligible for this clinical trial can expect to be enrolled in the study for about 24 weeks and will need to attend at least 10 study visits in-person or over the phone/video.
Participants will be randomly assigned to receive the study drug or placebo. The study doctor will not know who has been assigned to which drug.
PAXLOVID (nirmatrelvir and ritonavir) or placebo (drug with no active ingredient) and ritonavir, will need to be taken by mouth twice daily for 5 days (10 total doses).
Participants will need to track their doses and COVID-19 signs/symptoms in a diary.
This study may be an option for people who:
There are other requirements to participate in this study. A study team member will help determine if this study is right for you.